Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis

Digestive and Liver Disease

Volumn 44, Issue 2, 2012, Pages 149-153

  Arena, Umberto ^a   Stasi, Cristina ^a   Mannoni, Alessandro ^b   Benucci, Maurizio ^c   Maddali Bongi, Susanna ^a   Cammelli, Daniele ^a   Assarat, Ali ^a   Marra, Fabio ^a   Pinzani, Massimo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Sezione di Reumatologia ASL   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Liver fibrosis; Methotrexate; Non invasive; Rheumatoid arthritis; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; METHOTREXATE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; ELASTOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RIGIDITY; STEATOSIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84855721112     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.08.013     Document Type: Article

References (44)

1. Belinsky G.S., Parke A.L., Huang Q., et al. The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci 2007, 97:582-594.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 2002, 46:328-346.
3. Whiting-O'Keefe Q.E., Fye K.H., Sack K.D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90:711-716.
4. Visser K., Katchamart W., Loza E., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009, 68:1086-1093.
5. Richard S., Guerret S., Gerard F., et al. Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology 2000, 39:50-54.
6. Aithal G.P., Haugk B., Das S., et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment Pharmacol Ther 2004, 19:391-399.
7. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104.
8. Laharie D., Zerbib F., Adhoute X., et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006, 23:1621-1628.
9. Berends M.A., Snoek J., de Jong E.M., et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: FibroTest predicts the presence and FibroScan predicts the absence of significant liver fibrosis. Liver Int 2007, 27:639-645.
10. Park S.-H., Choe J.-Y., Kim S.-K. Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 2010, (May). [Epub ahead of print].
11. Laharie D., Seneschal J., Schaeverbeke T., et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010, 53:1035-1040.
12. Arena U., Vizzutti F., Abraldes J.G., et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008, 57:1288-1293.
13. Castéra L., Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?. Gut 2010, 59:861-866.
14. Mendes F.D., Levy C., Enders F.B., et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007, 102:344-350.
15. Viguier M., Allez M., Zagdanski A.M., et al. High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract. Hepatology 2004, 40:452-458.
16. Guido M., Rugge M. Liver fibrosis: natural history may be affected by the biopsy sample. Gut 2004, 53:1878.
17. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
18. Grundy S.M., Brewer Jr H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
19. Roulot D., Czernichow S., Le Clésiau H., et al. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008, 48:606-613.
20. Colombo S., Belloli L., Zaccanelli M., et al. Normal liver stiffness and its determinants in healthy blood donors. Dig Liver Dis 2011, 43:231-236.
21. Inoue S., Hashigichi M., Takagi K., et al. Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. Yakugaku Zasshi 2009, 129:843-849.
22. Hersh E.M., Wong V.G., Henderson E.S., et al. Hepatotoxic effects of methotrexate. Cancer 1966, 19:600-606.
23. Ahern M.J., Kevat S., Hill W., et al. Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings. Ann Rheum Dis 1991, 50:477-480.
24. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009, 146:489-503.
25. Berkun Y., Levartovsky D., Rubinow A., et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004, 63:1227-1231.
26. Ventura P., Rosa M.C., Abbati G., et al. Hyperhomocysteinaemia in chronic liver diseases: role of disease stage, vitamin status and methylenetetrahydrofolate reductase genetics. Liver Int 2005, 25:49-56.
27. Beyeler C., Reychen J., Thomann S.R., et al. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1997, 36:338-344.
28. Kremer J.M., Alarcon G.S., Lightfoot Jr R.W., et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Am Coll Rheumatol Arthritis Rheum 1994, 37:316-328.
29. Boffa M.J., Chalmers R.J., Haboubi N.Y., et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995, 133:774-778.
30. Malatjalian D.A., Ross J.B., Williams C.N., et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long-term follow-up. Can J Gastroenterol 1996, 10:369-375.
31. Tishler M., Caspi D., Halperin Z., et al. A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy. Rheumatol Int 1992, 12:39-41.
32. Kremer J.M., Kaye G.I., Kaye N.W., et al. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Followup over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995, 38:1194-1203.
33. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009, 62:481-492.
34. Pinzani M., Vizzutti F., Arena U., et al. Technology insight: non invasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008, 5:95-1006.
35. Zachariae H., Heickendorff L., Ségaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001, 143:100-103.
36. Chalmers R.J.G., Kirby B., Smith A., et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005, 152:444-450.
37. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
38. Castéra L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
39. Stasi C., Arena U., Vizzutti F., et al. Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: the missing tool?. Dig Liver Dis 2009, 41:863-866.
40. Nobili V., Vizzutti F., Arena U., et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008, 48:442-448.
41. Vizzutti F., Arena U., Marra F., et al. Elastography for the non-invasive assessment of liver disease: limitations and future developments. Gut 2009, 58:157-160.
42. Castéra L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51:828-835.
43. Parola M., Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001, 35:297-306.
44. Novo E., Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 2008, 1:5.